Cargando…
Phosphoinositide 3-kinase in Health and Disease Volume 2 /
From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in pro...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Berlin, Heidelberg :
Springer Berlin Heidelberg : Imprint: Springer,
2011.
|
| Edición: | 1st ed. 2011. |
| Colección: | Current Topics in Microbiology and Immunology,
347 |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-642-14816-3 | ||
| 003 | DE-He213 | ||
| 005 | 20220111134241.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 101029s2011 gw | s |||| 0|eng d | ||
| 020 | |a 9783642148163 |9 978-3-642-14816-3 | ||
| 024 | 7 | |a 10.1007/978-3-642-14816-3 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Phosphoinositide 3-kinase in Health and Disease |h [electronic resource] : |b Volume 2 / |c edited by Christian Rommel, Bart Vanhaesebroeck, Peter K. Vogt. |
| 250 | |a 1st ed. 2011. | ||
| 264 | 1 | |a Berlin, Heidelberg : |b Springer Berlin Heidelberg : |b Imprint: Springer, |c 2011. | |
| 300 | |a X, 306 p. 79 illus., 46 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Current Topics in Microbiology and Immunology, |x 2196-9965 ; |v 347 | |
| 520 | |a From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 700 | 1 | |a Rommel, Christian. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Vanhaesebroeck, Bart. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Vogt, Peter K. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783642265303 |
| 776 | 0 | 8 | |i Printed edition: |z 9783642148156 |
| 776 | 0 | 8 | |i Printed edition: |z 9783642148170 |
| 830 | 0 | |a Current Topics in Microbiology and Immunology, |x 2196-9965 ; |v 347 | |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-3-642-14816-3 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||